Skip to main content

Table 2 Clinical characteristics and next-generation sequencing results

From: Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations

  Histology EGFR Sequence Variants Frequency (%) Allele Call Exon 20 T790M Frequency (%) Conversion to SCLC Prior TKIs Duration (days)
Case 1 Adenocarcinoma Exon 19 44.3 Heterozygous Yes 7.2 No Erlotinib 681
E746_T750 del
Case 2 Adenocarcinoma Exon 19 59.4 Heterozygous No - No Gefitinib 537
E746_T751 del > A
Case 3 Adenocarcinoma Exon 21 L858R 46.1 Heterozygous No - No Gefitinib 195
Exon 18 T725R 30.6 Heterozygous
Case 4 Adenocarcinoma Exon 21 L858R 23.3 Heterozygous No - No Erlotinib 217
Exon 20 S768I 10.0 Heterozygous
Case 5 Adenocarcinoma Exon21 L858R 56.9 Heterozygous No - No Gefitinib 1105
Exon 18 E709G 54.5 Heterozygous
Case 6 Adenocarcinoma Exon 19 97.2 Homozygous Yes 21.8 No Erlotinib 693
E746_T750 del
Case 7 Adenocarcinoma Exon 21 L858R 13.8 Heterozygous Yes 5.2 No Erlotinib 537
Case 8 Squamous cell carcinoma Exon 19 86.9 Heterozygous Yes 7.3 No Erlotinib 315
E746_T750 del
Case 9 Adenocarcinoma Exon 19 65.3 Heterozygous Yes 41.3 No Erlotinib 1555
E746_T750 del
Case 10 Adenocarcinoma Exon21 L858R 11.2 Heterozygous Yes 4.8 No Gefitinib 1912
Case 11 Adenocarcinoma Exon 19 46.4 Heterozygous Yes 11.0 No Erlotinib 256
E746_T750 del
Case 12 Adenocarcinoma Exon21 L858R 22.2 Heterozygous No - No Erlotinib 924
Exon 21 G873R 10.8 Heterozygous
Case 13 Adenocarcinoma Exon 21 L861Q 59.9 Heterozygous No - No Gefitinib Erlotinib 1304
122
Exon 20 P772S 10.2 Heterozygous
Exon19 L747S 11.8 Heterozygous
Exon2 A289V 12.3 Heterozygous
Case 14 Adenocarcinoma Exon 19 80.82 Heterozygous Yes 14.8 No Erlotinib 392
E746_T750 del   
Case 15 Adenocarcinoma Exon21 L858R 76.7 Heterozygous Yes 10.3 No Erlotinib 339